Connor Clark & Lunn Investment Management Ltd. Acquires 234,810 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 176.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 367,594 shares of the company's stock after purchasing an additional 234,810 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned 0.68% of Fulcrum Therapeutics worth $1,728,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in FULC. Braidwell LP acquired a new position in Fulcrum Therapeutics during the 3rd quarter valued at about $3,817,000. State Street Corp raised its position in shares of Fulcrum Therapeutics by 61.4% in the 3rd quarter. State Street Corp now owns 1,680,229 shares of the company's stock valued at $5,998,000 after acquiring an additional 638,955 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of Fulcrum Therapeutics by 223.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 569,185 shares of the company's stock valued at $2,032,000 after acquiring an additional 393,202 shares during the period. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Fulcrum Therapeutics in the 3rd quarter valued at approximately $721,000. Finally, Barclays PLC raised its position in shares of Fulcrum Therapeutics by 367.1% in the 3rd quarter. Barclays PLC now owns 124,141 shares of the company's stock valued at $443,000 after acquiring an additional 97,565 shares during the period. 89.83% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a "neutral" rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a research report on Wednesday, February 26th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $8.63.

Fulcrum Therapeutics Stock Performance

FULC stock traded up $0.13 during mid-day trading on Friday, hitting $3.15. 1,228,809 shares of the company were exchanged, compared to its average volume of 945,824. The firm has a market cap of $170.03 million, a P/E ratio of -10.16 and a beta of 2.20. The firm's 50 day simple moving average is $3.62 and its 200 day simple moving average is $3.91. Fulcrum Therapeutics, Inc. has a 1-year low of $2.78 and a 1-year high of $10.13.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.03). On average, equities research analysts predict that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current fiscal year.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.